Skip to main content
 This program is not active.
On Demand

COVID-19 and Diabetes


Total Credits: .25 including .25 AOA Category 1-A Credit(s)

Average Rating:
Not yet rated
State Associations:
POMA - Pennsylvania
Faculty:
Jeffrey S. Freeman, DO, FACOI, FACP
Duration:
22 Minutes
Expiration:
Never expires.


Handouts

Faculty

Jeffrey S. Freeman, DO, FACOI, FACP's Profile

Jeffrey S. Freeman, DO, FACOI, FACP Related Seminars and Products


Jeffrey S. Freeman, DO, FACOI, FACP, “COVID-19 and Diabetes” and moderator of Thursday morning’s endocrinology session, is a member of the education committee for POMA’s 112th Annual Clinical Assembly and Scientific Seminar. A professor of internal medicine and chairman of the division of endocrinology and metabolism at the Philadelphia College of Osteopathic Medicine, he is also a physician with HAN Endocrinology Associates, Chester Crozer Medical Center in Springfield (Pa.). Board certified in internal medicine, endocrinology and clinical lipidology, Dr. Freeman is a graduate of the University of Hartford in West Hartford, Connecticut, and a 1978 graduate of Des Moines (Iowa) University — Osteopathic Medical Center College of Osteopathic Medicine and Surgery. He completed an internship at Pontiac (Mich.) Osteopathic Hospital, an internal medicine residency at John F. Kennedy Memorial Hospital in Stratford, New Jersey, and an endocrinology and metabolism fellowship at the University of Medicine and Dentistry of New Jersey in Newark. A fellow of the American College of Osteopathic Internists and the American College of Physicians, Dr. Freeman is a member of POMA, the Philadelphia County Osteopathic Medical Society, the American Osteopathic Association, the New Jersey Association of Osteopathic Physicians and Surgeons, past president of the American Diabetes Association Pennsylvania affiliate, the American Heart Association, the Thyroid Society of Philadelphia and board member of the Philadelphia Endocrinology Society.

Disclosure: Speaker’s bureau for Amarin Corporation; Amgen, Inc.; Novo Nordisk; and Valeritas, Inc.


Reviews